
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
According to a new study from the Tufts Center for the Study of Drug Development efforts by drug developers during the last decade to improve recruitment and retention appear to be paying off. Enrollment timelines now are equal to or shorter than planned timelines in 77% of studies, while a previous study in 2012 found that a high percentage of clinical trials had to extend planned timelines to achieve target enrollment.
For more of the report’s findings, click






